Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

@article{Wang2010ElevatedEO,
  title={Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin},
  author={S. Wang and X. Huang and C-K Lee and B. Liu},
  journal={Oncogene},
  year={2010},
  volume={29},
  pages={4225-4236}
}
The coexpression of erbB3 and erbB2 is frequently observed in breast cancer; and erbB3 has a critical role in erbB2 promotion of breast cancer progression and anti-estrogen resistance. In this study, we determine the role of erbB3 in erbB2-mediated paclitaxel resistance in breast cancer cells. The overexpression of exogenous erbB3 via either stable or transient transfection in erbB2-overexpressing, but not epidermal growth factor receptor (EGFR)-expressing, breast cancer cells significantly… 
Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
TLDR
Data indicate that increased expression of erbB3 plays a pivotal role in activating downstream PI-3K/Akt pathway and promotingErbB2-driven mammary/breast tumorigenesis, and simultaneous targeting of erBB2 and erb B3 with two IgG1 Abs may be an effective strategy to treat breast cancer patients whose tumors overexpress both erbBs.
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
TLDR
The combinations of MM-121 and paclitaxel not only inhibit tumor cell proliferation, but also promote erbB2-overexpressing breast cancer cells to undergo apoptosis via downregulation of Survivin in vitro and in vivo, suggesting that inactivation of erbbB3 withMM-121 enhances pac litaxel-mediated antitumor activity against erb B2-ovesrexpressed breast cancers.
ERBB2 Overexpression Establishes ERBB3-Dependent Hypersensitivity of Breast Cancer Cells to Withaferin A
TLDR
WA or derivatives of Withaferin A may present a low toxicity addition to ERBB2-targeting therapeutics, especially in cases in which ERBB3 involvement is driving resistance or reduced overall sensitivity.
Targeting of erbB3 receptor to overcome resistance in cancer treatment
TLDR
The role of erbB3-initiated signaling in the development of cancer drug resistance is focused on and the latest advances in identifying therapeutic strategies inactivating erBB3 to overcome the resistance and enhance efficacy of cancer therapeutics are discussed.
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
TLDR
The combination of MM-121 and trastuzumab not only inhibits erbBB2-overexpressing breast cancer cell proliferation, but also promotes the otherwise trastzumab-resistant cells undergoing apoptosis in an in vivo xenografts model.
Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
TLDR
It is shown that transfection of HER2 into MCF7 breast cancer cells (MCF7/HER2) resulted in an up-regulation of BCRP via the phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B (NF-κB) signaling, which played an important role in HER2-mediated chemoresistance of MCF 7 cells.
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
TLDR
A bispecific antibody suitable for both large scale production and systemic therapy by generating a single polypeptide fusion protein of two human scFv antibodies linked to modified human serum albumin, MM-111 is developed, effectively inhibiting ErbB3 signaling and showing antitumor activity in preclinical models that is dependent onErbB2 overexpression.
Role of erbB3 receptors in cancer therapeutic resistance.
TLDR
This review focuses on the latest advances in the understanding of erbB3-initiated signaling in the development of resistance to cancer treatments.
...
...

References

SHOWING 1-10 OF 50 REFERENCES
Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells
TLDR
The data indicates that erBB2/erbB3 heterodimerization is a prerequisite for erbB2 tyrosine kinase activation in mammary/breast cancer cells and that downregulation of ErbB3 inhibits erb B2‐associated procarcinogenic activity via inactivation of the PI‐3K/Akt pathway.
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
TLDR
It is shown that ErbB2 regulates survivin protein expression in Erb B2-overexpressing breast cancer cells, shedding new light on the mechanism by which ErbK2 overexpression protects against apoptotic stimuli in breast cancer and identifies therapeutic interventions to improve clinical outcomes in these aggressive tumors.
Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance
TLDR
It is found that ErbB2-overexpressing cells expressed higher levels of survivin in multiple breast cancer cell lines and patient samples, which correlated with the increased resistance to Taxol-induced apoptosis and combination treatment of Taxol with PI3K/Akt and Src inhibitor led to increased apoptosis.
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
TLDR
It is demonstrated that ErbBB2 overexpression and activity alone are insufficient to promote breast tumor cell division, andErbB3 is shown to be an essential partner in the transformation process, which functions as an oncogenic unit to drive breast cancer cell proliferation.
Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling
TLDR
Interactions were studied using mammary/breast cancer cell lines from wild-type rat c-neu gene transgenic mice and humans to suggest that activation of both ER and erbB2/erbB3 signaling is requisite for estrogen-induced mitogenesis and ErbB 2/neu tyrosine kinase activation.
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
TLDR
The detrimental effects of the erbB2 gene in cancers, with a focus on breast cancer, are discussed and ErbBB2-targeting strategies as potential therapies for Erb B2-overexpressing cancers are outlined.
HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
TLDR
It is reported that the class I isoform-selective HDACi entinostat (SNDX-275) preferentially inhibits cell proliferation/survival and inactivates downstream signaling in erbB2-overexpressing compared with basal breast cancer cells.
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
TLDR
It is proposed that trastuzumab resistance in breast cancer might be overcome by therapeutic strategies that jointly target erbB3, erBB2, and IGF-IR, which form a heterotrimeric complex in resistant cells.
ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells
TLDR
The data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21Cip1 that confers Taxol resistance of breast cancer cells.
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
TLDR
It was revealed that the survivin protein level was up-regulated by the coexpression of HER2 and EGFR, leading to the increased resistance against etoposide-induced apoptosis in breast cancer cells, and survivin levels and apoptosis resistance were decreased when cells were treated with Herceptin.
...
...